Crizotinib Ups PFS in ALK-Positive NSCLC
The ALK-inhibitor crizotinib leads to longer progression-free survival than chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer (NSCLC), according to results of a phase III clinical trial.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Lung Cancer | Non-Small Cell Lung Cancer